Companies in #Acute Kidney Injury
Found 3 companies operating in this sector.
Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, built around alternatives to steroids and JAK inhibitors. Its lead candidate, paridiprubart (EB05), is a first-in-class anti-TLR4 antibody that has completed late-stage study in acute respiratory distress syndrome, reporting a statistically significant reduction in adjusted 28-day mortality versus standard of care in an expanded 278-patient Phase 3 dataset; the molecule is also being studied in acute kidney injury and in a U.S. government-funded host-directed therapeutics platform study. A second program, EB06, is an anti-CXCL10 monoclonal antibody in a Phase 2 study in moderate-to-severe nonsegmental vitiligo, with site activation in Canada underway. The Nasdaq-listed entity was formed in June 2019, when the private Canadian company Edesa Biotech combined with Stellar Biotechnologies in a share exchange and began trading under the symbol EDSA; executive offices are in Markham, Ontario, in the Greater Toronto Area. The company remains pre-revenue, exited fiscal Q3 2026 with roughly $10.3 million of cash and a $5.4 million quarterly net loss, and augmented its balance sheet in August 2026 with a $25.0 million underwritten equity offering priced at $5.50 per unit.
Outset Medical is a San Jose, California-based medical technology company commercializing the Tablo Hemodialysis System, a compact all-in-one dialysis console that integrates water purification, on-demand dialysate production and cloud connectivity so that treatment can be delivered from the hospital setting to the home. The company was incorporated in 2003 as Home Dialysis Plus, Ltd., renamed Outset Medical in January 2015 and listed on Nasdaq in September 2020. Its installed base spans more than 1,000 U.S. healthcare facilities, and its commercial model combines Tablo console placements with recurring revenue from Tablo cartridges and other consumables, plus the Tablo Data Ecosystem (TabloHub, MyTablo and TabloDash). Outset signed a three-year agreement with HCA Healthcare in June 2026 covering a fleet refresh of Tablo systems with an aggregate contract value of approximately $40 million through 2028, and guided to $125-130 million of full-year 2026 revenue alongside a Q2 2026 gross margin of 42.0%.
XORTX Therapeutics is a late-stage clinical pharmaceutical company developing therapies for hyperuricemia-related disease, with a portfolio spanning gout and progressive kidney disease. Its lead program, XRx-026, is built on XORLO, a proprietary formulation of the xanthine oxidase inhibitor oxypurinol, and is aimed at gout patients who cannot tolerate or do not respond adequately to existing urate-lowering therapy: allopurinol is not tolerated by an estimated 3-5% of patients, and febuxostat carries a boxed warning for cardiovascular risk. The company has outlined a regulatory pathway in which an Investigational New Drug application for XRx-026 is targeted to the fourth quarter of 2026, followed by the two-part XRX-OXY-102 study to characterize pharmacokinetics and efficacy and commercial-scale manufacturing for a first year of launch, with an NDA submission targeted approximately one year out. Earlier-stage assets include XRx-008 for autosomal dominant polycystic kidney disease and XRx-101 for acute kidney injury associated with respiratory viral infection, including sepsis.